{"id":"https://openalex.org/W2094916879","doi":"https://doi.org/10.1158/1535-7163.mct-14-0710","title":"The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents","display_name":"The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents","publication_year":2015,"publication_date":"2015-01-08","ids":{"openalex":"https://openalex.org/W2094916879","doi":"https://doi.org/10.1158/1535-7163.mct-14-0710","mag":"2094916879","pmid":"https://pubmed.ncbi.nlm.nih.gov/25567130"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-14-0710","doi":"https://doi.org/10.1158/1535-7163.mct-14-0710","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0710","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016057308","display_name":"Jude R. Canon","orcid":"https://orcid.org/0009-0005-3149-4247","observed_orcids":["https://orcid.org/0009-0005-3149-4247"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jude Canon","raw_affiliation_strings":["1Department of Oncology Research, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Oncology Research, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060909099","display_name":"Tao Osgood","orcid":"https://orcid.org/0009-0000-4393-0441","observed_orcids":["https://orcid.org/0009-0000-4393-0441"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tao Osgood","raw_affiliation_strings":["1Department of Oncology Research, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Oncology Research, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057300426","display_name":"Steven H. Olson","orcid":"https://orcid.org/0000-0001-9615-9355","observed_orcids":["https://orcid.org/0000-0001-9615-9355"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven H. Olson","raw_affiliation_strings":["2Department of Medicinal Chemistry, Amgen Inc., San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Medicinal Chemistry, Amgen Inc., San Francisco, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053466224","display_name":"Anne Y. Saiki","orcid":"https://orcid.org/0000-0003-3913-1860","observed_orcids":["https://orcid.org/0000-0003-3913-1860"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Y. Saiki","raw_affiliation_strings":["1Department of Oncology Research, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Oncology Research, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047510881","display_name":"Rebecca Axelsson Robertson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca Robertson","raw_affiliation_strings":["1Department of Oncology Research, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Oncology Research, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104109910","display_name":"Dongyin Yu","orcid":"https://orcid.org/0009-0009-6804-285X","observed_orcids":["https://orcid.org/0009-0009-6804-285X"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dongyin Yu","raw_affiliation_strings":["1Department of Oncology Research, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Oncology Research, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054284746","display_name":"John E. Eksterowicz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Eksterowicz","raw_affiliation_strings":["3Department of Molecular Structure, Amgen Inc., San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Molecular Structure, Amgen Inc., San Francisco, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045218258","display_name":"Qiuping Ye","orcid":"https://orcid.org/0009-0008-9039-0124","observed_orcids":["https://orcid.org/0009-0008-9039-0124"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qiuping Ye","raw_affiliation_strings":["4Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., San Francisco, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008009084","display_name":"Lixia Jin","orcid":"https://orcid.org/0000-0001-8018-9779","observed_orcids":["https://orcid.org/0000-0001-8018-9779"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lixia Jin","raw_affiliation_strings":["4Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., San Francisco, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076838621","display_name":"Ada Chen","orcid":"https://orcid.org/0000-0001-7748-0434","observed_orcids":["https://orcid.org/0000-0001-7748-0434"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ada Chen","raw_affiliation_strings":["3Department of Molecular Structure, Amgen Inc., San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Molecular Structure, Amgen Inc., San Francisco, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100615656","display_name":"Jing Zhou","orcid":"https://orcid.org/0000-0002-2453-6470","observed_orcids":["https://orcid.org/0000-0002-2453-6470"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Zhou","raw_affiliation_strings":["3Department of Molecular Structure, Amgen Inc., San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Molecular Structure, Amgen Inc., San Francisco, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066972897","display_name":"David H. Cordover","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Cordover","raw_affiliation_strings":["5Department of Pathology, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Department of Pathology, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Stephen Kaufman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Kaufman","raw_affiliation_strings":["5Department of Pathology, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Department of Pathology, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110966809","display_name":"Richard L. Kendall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Kendall","raw_affiliation_strings":["1Department of Oncology Research, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Oncology Research, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003571412","display_name":"Jonathan D. Oliner","orcid":"https://orcid.org/0009-0005-7397-3975","observed_orcids":["https://orcid.org/0009-0005-7397-3975"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan D. Oliner","raw_affiliation_strings":["1Department of Oncology Research, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Oncology Research, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001120662","display_name":"Angela Coxon","orcid":"https://orcid.org/0009-0000-3341-0645","observed_orcids":["https://orcid.org/0009-0000-3341-0645"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela Coxon","raw_affiliation_strings":["1Department of Oncology Research, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Oncology Research, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078787495","display_name":"Robert Radinsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Radinsky","raw_affiliation_strings":["1Department of Oncology Research, Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Oncology Research, Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1320553840"],"apc_list":null,"apc_paid":null,"fwci":4.7127,"has_fulltext":false,"cited_by_count":149,"citation_normalized_percentile":{"value":0.9684122,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"14","issue":"3","first_page":"649","last_page":"658"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10934","display_name":"Heat shock proteins research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mdm2-inhibitors","display_name":"MDM2 inhibitors","score":0.8949999809265137},{"id":"https://openalex.org/keywords/p53-activation","display_name":"p53 activation","score":0.7839999794960022},{"id":"https://openalex.org/keywords/p53-mdm2-interaction","display_name":"p53-MDM2 interaction","score":0.9890000224113464},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5860000252723694},{"id":"https://openalex.org/keywords/dna-damage","display_name":"DNA damage","score":0.5180000066757202},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.7269999980926514},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.968999981880188},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.9070000052452087},{"id":"https://openalex.org/keywords/mdm2-amplification","display_name":"MDM2 amplification","score":0.9129999876022339},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.9340000152587891}],"concepts":[{"id":"https://openalex.org/C2776192174","wikidata":"https://www.wikidata.org/wiki/Q18028978","display_name":"Mdm2","level":3,"score":0.8021095395088196},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5816245079040527},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5485560894012451},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5376924276351929},{"id":"https://openalex.org/C105696609","wikidata":"https://www.wikidata.org/wiki/Q1068809","display_name":"Cell cycle checkpoint","level":4,"score":0.5282822251319885},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.5216175317764282},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4671836197376251},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.43412482738494873},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.4224306643009186},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.41986095905303955},{"id":"https://openalex.org/C2779707156","wikidata":"https://www.wikidata.org/wiki/Q5611758","display_name":"Growth inhibition","level":3,"score":0.41240835189819336},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.36811304092407227},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34878700971603394},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3028731346130371},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.29777997732162476},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12045061588287354},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08587145805358887},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000085","descriptor_name":"Acetates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D003603","descriptor_name":"Cytotoxins","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010881","descriptor_name":"Piperidones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016159","descriptor_name":"Tumor Suppressor Protein p53","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019073","descriptor_name":"HT29 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D045325","descriptor_name":"HCT116 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051736","descriptor_name":"Proto-Oncogene Proteins c-mdm2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D059447","descriptor_name":"Cell Cycle Checkpoints","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D061986","descriptor_name":"MCF-7 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1158/1535-7163.mct-14-0710","doi":"https://doi.org/10.1158/1535-7163.mct-14-0710","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0710","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:25567130","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25567130","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.828.4682","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.828.4682","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/early/2015/02/12/1535-7163.MCT-14-0710.full.pdf","raw_type":"text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.843.6369","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.843.6369","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/14/3/649.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W1650797637","https://openalex.org/W1965173366","https://openalex.org/W1985135871","https://openalex.org/W1991167758","https://openalex.org/W1999707056","https://openalex.org/W2007935491","https://openalex.org/W2008887283","https://openalex.org/W2023486531","https://openalex.org/W2023623233","https://openalex.org/W2068577449","https://openalex.org/W2090240238","https://openalex.org/W2095805440","https://openalex.org/W2097933346","https://openalex.org/W2098748257","https://openalex.org/W2099293745","https://openalex.org/W2113782793","https://openalex.org/W2129769331","https://openalex.org/W2145973487"],"related_works":["https://openalex.org/W7099232122","https://openalex.org/W1525871272","https://openalex.org/W2494522857","https://openalex.org/W3013596866","https://openalex.org/W2397428234","https://openalex.org/W3113171218","https://openalex.org/W1596376363","https://openalex.org/W1992947288","https://openalex.org/W2097933346","https://openalex.org/W3204277805"],"abstract_inverted_index":{"p53":[0,21,34,65,84,139,154],"is":[1,7,39,49],"a":[2,28,40,173],"critical":[3],"tumor":[4,70,93,106],"suppressor":[5],"and":[6,48,61,81,90,108,112,122,138,147,149,175],"the":[8,18,45,56,75,100,162],"most":[9],"frequently":[10],"inactivated":[11],"gene":[12],"in":[13,51,67,101,142,156,168,176],"human":[14],"cancer.":[15],"Inhibition":[16],"of":[17,20,44,58,92,104,115,124,129,153,165],"interaction":[19,47],"with":[22,78,132,178],"its":[23,62],"negative":[24],"regulator":[25],"MDM2":[26,76],"represents":[27],"promising":[29],"clinical":[30,52,169],"strategy":[31],"to":[32,87,110],"treat":[33],"wild-type":[35],"tumors.":[36,157],"AMG":[37,59,72,96,130,166],"232":[38,60,73,97,131,167],"potential":[41],"best-in-class":[42],"inhibitor":[43],"MDM2-p53":[46],"currently":[50],"trials.":[53],"We":[54],"characterized":[55],"activity":[57,140],"effect":[63],"on":[64],"signaling":[66,155],"several":[68,105],"preclinical":[69,159],"models.":[71],"binds":[74],"protein":[77],"picomolar":[79],"affinity":[80],"robustly":[82],"induces":[83],"activity,":[85],"leading":[86],"cell-cycle":[88],"arrest":[89,121],"inhibition":[91],"cell":[94],"proliferation.":[95],"treatment":[98],"inhibited":[99],"vivo":[102],"growth":[103,120],"xenografts":[107],"led":[109],"complete":[111],"durable":[113],"regression":[114],"MDM2-amplified":[116],"SJSA-1":[117],"tumors":[118],"via":[119],"induction":[123],"apoptosis.":[125],"Therapeutic":[126],"combination":[127,177],"studies":[128],"chemotherapies":[133],"that":[134],"induce":[135],"DNA":[136],"damage":[137],"resulted":[141],"significantly":[143],"superior":[144],"antitumor":[145],"efficacy":[146],"regression,":[148],"markedly":[150],"increased":[151],"activation":[152],"These":[158],"data":[160],"support":[161],"further":[163],"evaluation":[164],"trials":[170],"as":[171],"both":[172],"monotherapy":[174],"standard-of-care":[179],"cytotoxics.":[180]},"counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":14},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":14},{"year":2022,"cited_by_count":19},{"year":2021,"cited_by_count":23},{"year":2020,"cited_by_count":14},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}